CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Atomoxetine hydrochloride

Last Updated: September 25, 2006
Result type: Reports
Project Number: SF0085-000
Product Line: Reimbursement Review

Generic Name: Atomoxetine hydrochloride

Brand Name: Strattera

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Attention deficit hyperactivity disorder

Indications: Attention deficit hyperactivity disorder

Submission Type: Request For Advice

Project Status: Complete